Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Heat shock protein family B member 2 (HSPB2) is a small heat-shock protein with a conserved α-crystallin domain and is predominantly expressed in heart and skeletal muscle. It acts as a molecular chaperone, preventing protein aggregation and assisting in protein folding during stress conditions. HSPB2 specifically binds to and activates the myotonic dystrophy protein kinase (DMPK), playing crucial roles in muscle structure maintenance and function. While HSPB2 is not heat-inducible, it participates broadly in cytoprotection, protein quality control, and cellular homeostasis, and is implicated in cardiac, muscular, and neurodegenerative diseases, often elevated in disease states as a compensatory response[1][2][3][4][6]. No clinically relevant small molecule or biologic drugs are known to selectively target HSPB2, and its primary recognized function is as a molecular chaperone—not a receptor, enzyme, or transporter.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heat shock protein family B member 2 (HSPB2).